HNRNPD Antibodies

Heterogeneous nuclear ribonucleoprotein D0 (HNRNPD)

Binds with higher affinity to RNA molecules that contain AU-rich elements (AREs) found within the 3'-UTR of several proto- oncogenes and cytokine mRNAs. Also binds to double- and single- stranded DNA sequences in a specific manner and functions a transcription factor.

Each of the RNA-binding domains namely may bind solely to a single-stranded non-monotonous 5'-UUAG-3' sequence and also weaker to the single-stranded 5'-TTAGGG-3' telomeric DNA repeat. Binds RNA oligonucleotides with 5'-UUAGGG-3' repeats more tightly than the telomeric single-stranded DNA 5'- TTAGGG-3' repeats.

Gene Information

Human
Gene Name:	HNRNPD
Uniprot:	Q14103
Entrez:	3184

Family

Belongs to:
No superfamily

Alternative Names

AUF1A; heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein1, 37kDa); heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA-binding protein1, 37kD); heterogeneous nuclear ribonucleoprotein D0; hnRNPD0; type A

Molecular Weight

Mass (kDA):
38.434 kDA

Genomic Context

Human
Location:	4q21.22
Sequence:	4; NC_000004.12 (82352498..82373996, complement)

Subcellular Localizations

Nucleus. Cytoplasm. Localized in cytoplasmic mRNP granules containing untranslated mRNAs. Component of ribonucleosomes. Cytoplasmic localization oscillates diurnally.

Diseases

• Cell Transformation, Neoplastic
• Neoplasms
• Sarcoma
• Malignant Neoplasms
• Speech Delay
• Sarcoma, Experimental
• Lymphoma
• Cytogenetic Abnormality
• Contact Hypersensitivity
• Pathologic Neovascularization
• Pruritus

• Dermatitis
• Language Development Disorders
• Ki-1+ Anaplastic Large Cell Lymphoma
• Muscle Hypotonia
• Haploinsufficiency

Interacting Proteins

• EIF4G1
• HNRNPA2B1
• HNRNPU
• IGF2BP2
• ING4

• LDHAL6B
• PABPC1
• SFN
• SYNCRIP
• YBX1

Pathways

• Hyperphosphorylation
• Cell Proliferation
• Hypersensitivity
• Regulation Of Mrna Stability
• Oncogenesis

PTMs

• Phosphorylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/HNRNPD

Best Uses Of The HNRNPD Marker

The Anti-hnRNP/AUF1/HNRNPDMarker is a versatile diagnostic instrument for the detection and analysis of antibodies to HNRNPD. We will discuss the use, validity, cost, and price of this antibody in this article. It is easy to use this antibody in your research. Continue reading to learn more. You can also browse the Boster bio website.

Anti-hnRNP D/AUF1/HNRNPD Marker

The HNRNPD marker is a tyrosine kinase inhibitor that is a key protein in the cell cycle. In vivo, HNRNPK promotes tumorigenesis when it is reduced. HNRNPD reduced the proliferation of BCR/ABL+ cells, according to a study. The HNRNPD marker: Best Uses

High-affinity monoclonal antibodies developed by Boster Bio are validated to detect HNRNPD. These antibodies are validated on Western Blotting, Immunohistochemistry, and ELISA and are trusted by the scientific community. Boster also offers a variety combinations. The customer can choose the conjugate when ordering a monoclonal anti-body.

A more specific marker than p40, hnRNPD is used to differentiate squamous cell carcinoma from its normal counterparts. It is expressed within the nucleus of squamous carcinoma cells. Normal tissue specimens have negligible nuclear immunestaining. Both p40 and hnRNPD have been used to differentiate squamous cell carcinoma, and hnRNPD can be used as a potential diagnostic marker.

HNRNPh2 is a key regulator of the PI3K/AKT pathway. HNRNPh2 regulates PTPN6 and is a member a RBPs which regulate PTPN6. These findings may help us understand the metabolic dysfunctions associated with CML disease progression. Best Uses Of The HNRNPD Marker

Applications

The HNRNPD gene is highly expressed in glioma tissues and cells, and overexpression of this protein inhibits the growth of VMs. However, it is not known whether overexpression of HNRNPD or overexpression of miR-651-3p can cause VMs. The HNRNPD gene is an important regulator of glioma cell invasion, migration, and metabolism.

The HNRNPD gene regulates stability and transcription in addition to transcriptional regulation. HNRNPD inhibits the expression of c-Myc mRNA, whereas HNRNPF increases the stability of Snail1 mRNA. HNRNPD promotes migration of colon cancer cells and epithelial-mesenchymal transition of bladder cancer cells.

Immunoprecipitates of the hnRNPD gene were prepared for immunoblotting and subsequent liquid chromatography-tandem mass spectrometry. To identify HNRNPD genes binding partners, IP-LC/MS/MS was used. Bioinformatics as well as cellular networks were used for the determination of protein-protein interactions. HNRNPD may be a highly dynamic, RNA-binding protein. Its overexpression may lead to poor prognosis in the fight against cancer.

These findings suggest that HNRNPD expression can be used as a prognostic indicator in OSCC. Furthermore, it may be useful in defining a high-risk subgroup of patients. This could address a pressing need for better stratification strategies. These strategies may improve patient care. HNRNPD is a prognostic gene that can be used to identify OSCC risky patients and their response chemotherapy.

Validation methods

The validation methods for the HNRNPD Marker involve the use of short hairpin RNA (siRNA). The siRNA targets the hnRNPD1 gene. These siRNAs are available in lentivirus, AAV, or oligo format, and have been used to knock down the HNRNPD gene in various host cells. The HNRNPD siRNA can be used for research purposes only. It is not intended for diagnostic or therapeutic purposes.

Cost

The HNRNPD gene is a novel genetic marker in the development of a new, independent OSCC diagnostic test. The cost of this new test remains unknown but could be a good investment in this innovative research. The marker will not only provide a new diagnostic tool for OSCC patients, but it could also help identify high-risk subgroups of OSCC patients. It may even lower the overall cancer cost.